¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"progressive cleavage"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • progressive diffuse keratoderma
    ±¤¹üÀ§ÁøÇà°¢ÁúÇǺÎÁõ
  • progressive disseminated histoplasmosis
    ÁøÇàÆÄÁ¾È÷½ºÅäÇö󽺸¶Áõ
  • progressive external ophthalmoplegia
    ÁøÇà¹Ù±ù´«±ÙÀ°¸¶ºñ
  • progressive hypertrophic interstitial neuritis
    ÁøÇàºñ´ë»çÀÌÁú½Å°æ¿°, ÁøÇàºñ´ë°£Áú½Å°æ¿°
  • progressive lingual hemiatrophy
    ÁøÇàÇô¹ÝÀ§ÃàÁõ
  • progressive mean
    ´©°¡Æò±Õ
  • progressive multifocal leukoencephalopathy
    ÁøÇà´ÙÃÊÁ¡¹é(»ö)Áú³úº´(Áõ)
  • progressive muscular dystrophy
    ÁøÇà±Ù(À°)µð½ºÆ®·ÎÇÇ
  • progressive myopia
    ÁøÇà±Ù½Ã
  • progressive nuclear ophthalmoplegia
    ÁøÇà½Å°æÇÙ´«±ÙÀ°¸¶ºñ
  • progressive outer retinal necrosis
    ÁøÇ༺¿Ü¸Á¸·±«»ç
  • progressive pigmentary dermatosis
    ÁøÇà»ö¼ÒÇǺκ´
  • progressive resistance
    Á¡ÁõÀúÇ×
  • progressive resistance exercise
    Á¡ÁõÀúÇ׿
  • progressive spastic spinal paralysis
    ÁøÇà°­Á÷ô¼ö¸¶ºñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • progressive muscular dystrophy
    ÁøÇà±ÙÀ°ÅðÇàÀ§Ãà
  • progressive pigmentary dermatosis
    ÁøÇà»ö¼ÒÇǺκ´
  • progressive resistance exercise
    Á¡ÁõÀúÇ׿
  • progressive subcortical encephalopathy
    ÁøÇà°ÑÁú¹Ø³úº´Áõ
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • malignant progressive histiocytoma
    ¾Ç¼ºÁøÇàÁ¶Á÷±¸Á¾
  • progressive disseminated histoplasmosis
    ÁøÇàÆÄÁ¾È÷½ºÅäÇö󽺸¶Áõ
  • progressive lingual hemiatrophy
    ÁøÇàÇô¹ÝÀ§ÃàÁõ
  • progressive diffuse keratoderma
    ±¤¹üÀ§ÁøÇà°¢ÁúÇǺÎÁõ
  • progressive cardiomyopathic lentiginosis
    ÁøÇà½ÉÀå±ÙÀ°º´Èæ»öÁ¡Áõ
  • progressive multifocal leukoencephalopathy
    ÁøÇà´ÙÃÊÁ¡¹é»öÁú³úÁõ
  • progressive mean
    ´©°¡Æò±Õ
  • progressive myopia
    ÁøÇà±Ù½Ã
  • progressive hypertrophic interstitial neuritis
    ÁøÇàºñ´ë»çÀÌÁú½Å°æ¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • progressive mean
    ´©°¡Æò±Õ(ËÈ˧̰˻).
  • progressive multifocal leukoencephalopathy
    ÁøÇ༺ ´Ù¹ß¼º ¹éÁú³ú(º´)Áõ
  • progressive multifocal leukoencephalopathy
    ÁøÇ༺ ´ÙÃÊÁ¡¼º ¹éÁú³úº´Áõ(òäú¼àõ Òýõ¥ïÇàõ ÛÜòõÒàÜ»ñø)
  • progressive muscle dystrophy
    ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ(òäú¼àõÐÉì¶ç½å×ñø).
  • progressive muscle dystrophy
    ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ(òäú¼àõ ì¶ç½å×ñø)
  • progressive myopathy
    ÁøÇ༺ ±Ùº´Áõ(¡­ÐÉÜ»ñø).
  • progressive myopathy
    ÁøÇ༺ ±Ùº´Áõ(òäú¼àõ ÐÉÜ»ñø)
  • progressive myopia
    ÁøÇ༺ ±Ù½Ã(òäú¼àõ ÐÎãÊ) ¾Æµ¿ÀÇ
  • progressive neural muscular atrophy
    ÁøÇ༺ ½Å°æ¼º ±ÙÀ§Ãà(¡­ãêÌèàõÐÉê×õê).
  • progressive neural muscular atrophy
    ÁøÇ༺ ½Å°æ¼º ±ÙÀ§Ãà(òäú¼àõ ãêÌèàõ ÐÉê×õê)
  • progressive nodular fibrosis of the skin
    ÁøÇ༺ °áÀý ÇǺΠ¼¶À¯Áõ
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ÇÙ¼º¾È±Ù¸¶ºñ.
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ ÇÙ¼º ¾È±Ù¸¶ºñ(òäú¼àõ ú·àõ äÑÐÉØ¦Ýö)
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ÇÙ¼º¾È±Ù¸¶ºñ
  • progressive ophtalmoplegia
    ÁøÇ༺ ¾È±Ù ¸¶ºñ(òäú¼àõ äÑÐÉØ¦Ýö)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • meroblastic cleavage
    ºÎºÐºÐÇÒ
  • mosaic cleavage
    ¸ðÀÚÀÌÅ©¼º ³­ÇÒ(¡­àõÕ°ùÜ).
  • partial cleavage ³ª segmentatio partialis
    ºÎºÐºÐÇÒ(Ý»ÝÂÝÂùÜ).
  • radial cleavage
    ºÎê»ìºÐÇÒ
  • right spiral cleavage
    ¿À¸¥³ª¼±ºÐÇÒ
  • spiral cleavage
    ³ª¼±³­ÇÒ(¡­Õ°ùÜ).
  • spiral cleavage
    ³ª¼±ºÐÇÒ
  • superficial cleavage
    Ç¥ÃþºÐÇÒ
  • surface cleavage
    Ç¥ÇǺÐÇÒ(øúù«ÝÂùÜ).
  • unequal cleavage
    ºÒ±ÕµîºÐÇÒ
  • acquired progressive lymphangioma
    ÈÄõ¼º ÁøÇ༺ ¸²ÇÁ°üÁ¾
  • ataxic locomotrice progressive
    ÁøÇ༺ À̵¿ ¿îµ¿½ÇÁ¶.
  • chronic progressive disciform granulomatosis
    ¸¸¼º ÁøÇ༺ ¿øÆÇ»ó À°¾ÆÁ¾Áõ
  • chronic progressive external ophthalmoplegia
    ¸¸¼ºÁøÇ༺¿Ü¾È±Ù¸¶ºñ
  • dystrophia musculorum progressive ³ª
    ÁøÇ༺ ±ÙÀ°ÀÌ¿µ¾ç(Áõ)(òäú¼àõÐÉë¿ì¶ç½å×ñø).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SC conditioned stimulus; sacrococcygeal; Sanitary Corps; scalenus [muscle]; scapula; Schwann cell; scia...
TC target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin...
PMF Progressive Massive Fibrosis
  = Silicosis
PRP   1) Progressive Rubella Panencephalitis
  2) Platelet Rich Plasma
 &...
RPGN Rapidly Progressive Glomerulo-Nephritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SCAP SREBP cleavage activating protein
SCC Side-chain cleavage
SCC side chain cleavage enzyme
CPEO Chronic Progressive External Ophthalmoplegia
OPP Ovine progressive pneumonia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • symmetrical progressive erythrokeratoderma
    ´ëμº ÁøÇ༺ È«¹Ý °¢ÇÇÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
total cleavage Cleavage in which the blastomeres are completely separated; the entire egg participates in cell division.
Synonym: complete cleavage, total cleavage.
(05 Mar 2000)
enamel cleavage The splitting of enamel in a plane parallel to the direction of the enamel rods.
(05 Mar 2000)
equal cleavage Cleavage producing blastomeres of like size.
(05 Mar 2000)
equatorial cleavage Cleavage in which the plane of cytoplasmic division is at right angles to the axis of the ovum.
(05 Mar 2000)
yolk cleavage Segmentation of the vitellus.
(05 Mar 2000)
unequal cleavage Cleavage producing blastomeres of different sizes at the two poles.
(05 Mar 2000)
freeze cleavage Method of specimen preparation for the electron microscope in which rapidly frozen tissue is cracked so as to produce a fracture plane through the specimen. The surface of the fracture plane is then shadowed by heavy metal vapour, strengthened by a carbon film and the underlying specimen is digested away, leaving a replica that can be picked up on a grid and examined in the transmission electron microscope. The great advantage of the method is that the fracture plane tends to pass along the centre of lipid bilayers and it is therefore possible to get en face views of membranes that reveal the pattern of Integral membrane proteins. The E face is the outer lamella of the plasma membrane viewed as if from within the cell, the P face the inner lamella viewed from outside the cell. Fracture planes also often pass along lines of weakness such as the interface between cytoplasm and membrane, so that outer and inner membrane surfaces can be viewed. Further information about the structure can be revealed by freeze etching. Extremely rapid freezing followed by deep etching has allowed the structure of the cytoplasm to be studied without the artefacts that might be introduced by fixation.
(18 Nov 1997)
aphasia, primary progressive A type of aphasia appearing gradually and gradually worsening without any major change in other cognitive functions. It is regarded by some authors as a syndrome which may be due to various degenerative diseases of the cerebral cortex (notably alzheimer disease, owing to its frequency), while others see in it an autonomous disease related to a neuropathological process that is distinct from the main degenerative dementias. The principal clinical peculiarity of primary progressive aphasia is that it spares the patient's autonomy for a long time, but ultimately turns into global dementia.
(12 Dec 1998)
bovine progressive degenerative myeloencephalopathy A familiar myeloencephalopathy of brown Swiss cattle characterised by bilateral hindleg weakness and ataxia and deficient proprioceptive reflexes.
(05 Mar 2000)
rapidly progressive glomerulonephritis <nephrology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
chronic progressive chorea A progressive disorder usually beginning in young to middle age, consisting of a triad of choreoathetosis, dementia, and autosomal dominant inheritance with complete penetrance. Bilateral marked wasting of the putamen and the head of the caudate nucleus is characteristic.
Synonym: chronic progressive chorea, degenerative chorea, hereditary chorea, Huntington's disease.
(05 Mar 2000)
chronic progressive external ophthalmoplegia A specific type of slowly worsening weakness of the ocular muscles, usually associated with a pigmentary retinopathy.
See: Kearns-Sayre syndrome, oculopharyngeal dystrophy.
Synonym: ocular myopathy.
(05 Mar 2000)
chronic progressive syphilitic meningoencephalitis Syphilitic infection manifested as dementia (often with delusional features), dysarthria, seizures, myoclonic jerks, action tremor, impaired walking and standing, pupillary abnormalities, and abnormal CSF findings.
Synonym: chronic progressive syphilitic meningoencephalitis.
(05 Mar 2000)
pneumonia, progressive interstitial, of sheep Chronic respiratory disease caused by the visna-maedi virus. It was formerly believed to be identical with jaagsiekte (pulmonary adenomatosis, ovine) but is now recognised as a separate entity.
(12 Dec 1998)
primary progressive cerebellar degeneration A familial ataxic condition related to cerebellar degeneration.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á